The Wisconsin Alumni Research Foundation claimed that have provides Pfizer the rights to work with human embryonic stem cells for drug research and discovery.
Renowned pharmaceutical company Pfizer Inc. also announced Tuesday it has signed the license with the Wisconsin Alumni Research Foundation to use human embryonic stem cells for the development of new drug therapies.
WARF holds several key patents that broadly cover the preparation of embryonic stem cells, which are the basic material from which virtually all organs, cells and other body tissues are formed. The patents are based on the work of James Thomson, a University of Wisconsin-Madison scientist.
Pfizer is the biggest of the 35 companies to sign an embryonic stem cell license with the foundation. Other famous include Invitrogen Corp. of Carlsbad, Calif., and BD Biosciences, part of Becton, Dickinson & Co., based in Franklin Lakes, N.J., and Vancouver, British Columbia. WARF also has issued 964 embryonic stem cell licenses to academic researchers.
In November 2008, Pfizer launched the Pfizer Regenerative Medicine research unit. Pfizer researchers and scientists are working to discover and develop new ways to treat and prevent life-threatening and debilitating illnesses, as well as to improve wellness and quality of life.
According to Wisconsin Gov. Jim Doyle having these two giants in the field of biopharmaceutical research and stem cell research come together brings a step closer towards finding relief from diseases like diabetes, Alzheimer’s, Parkinson’s, multiple sclerosis and cancer.
Wisconsin Gov. Jim Doyle is now looking forward to find relief from diseases like diabetes, Alzheimer’s, Parkinson’s, multiple sclerosis and cancer. He believes that having these two giants in the field of biopharmaceutical research and stem cell research they are surely a step forward to find relieves against killer diseases.